Julian Upton

A panel of pharma digital leaders discusses pathways for technology and data scale-up—and the skills, mindset, and C-suite influence needed to drive true digital transformation.

Going all-in on accelerating the promise of cell therapy at larger scale.

From big pharma to underdog biotech, a mission to empower.

Applying a love for numbers in tackling drug-access delays around the world.

Pharm Exec speaks to David Hysong, founder and Chief Executive Officer of SHEPHERD, whose mission, stated simply, is ”to make the drugs other companies won’t make to save lives others aren’t saving.”

Henry McNamara, Senior Vice President and General Manager, Oracle Health Sciences, reviews the lessons that the industry has learned over the last year and looks at what lies ahead for pharma in 2021.

Dr. Matthias Schmidt talks about his new role leading the US subsidiary of Japan’s JCR Pharmaceuticals after a “far-from-easy” merger last year.

Francesca Properzi and Sudip Sinha talk about how the results of an inaugural Clinical Trial Digital Tracker Survey indicate that many clinical trials organizations are still reluctant to integrate digital technologies into their processes.

Melissa Thompson, Alcon’s head of global corporate social responsibility, discusses her career commitment to CSR and how COVID-19 has impacted the organization’s efforts to improve access to eye care around the globe.

With the UK maintaining a world-leading position in key areas of technology, 2021 could be a banner year for its life sciences.

Melissa Fellner of AstraZeneca and Leonie Goddard of Veeva, talk to Pharm Exec about how AZ’s mission to transform its digital strategies to better connect with customers.

Laura Barrell, Senior Associate at VWV, outlines how the UK is emerging from the trials of Brexit and COVID to take a leading international role in the future of pharma and healthcare.

Sam Pearce, SVP, Head of Europe and International at Jazz Pharmaceuticals, talks about joining the company during a transformative period and how she is working to foster a bold and collaborative culture to expand Jazz’s footprint in Europe and beyond.

Cathy Traz of Bristol Myers Squibb outlines the mission of the COVID Advocacy Exchange, a virtual platform that convenes advocacy groups, patients, and industry for increased connection and collaboration.

Dr. Husseini Manji talks to Pharm Exec about his new role as J&J's Head of Science for Minds and how he hopes to foster new ways to treat dementia and serious mental disorders and provide holistic mental care.

EXUMA Biotech's Dr. Greg Frost talks about his work making CAR-T cell therapy readily accessible and affordable.

Patrick Soon-Shiong, the billionaire biotech entrepreneur and owner of NantWorks, a network of health startups, discusses his companies’ COVID-19 vaccine candidate and its “fighting chance” to outsmart the virus’s hidden tricks through merging supercomputing and modernized DNA delivery.

Titan Pharmaceuticals' Sunil Bhonsle and Indegene's Jamie Peck talk about their new partnership and how it will move forward in the post-COVID environment.

Immunomedics’ CFO/CBO Usama Malik discusses how a lot of good planning and a little good fortune helped the company to achieve its “virtual launch” amid the coronavirus crisis.

Physician, company CEO, surgeon, philanthropist, and owner of the LA Times, Dr. Patrick Soon-Shiong talks about his progress developing a COVID-19 treatment and his goal to produce a billion doses to tackle the virus worldwide.

Pharm Exec speaks with Arndt Rolfs, CEO and founder of CENTOGENE, who discusses his company’s rise from a small genetic diagnostics startup to a global organization focused on advancing the understanding of the pathophysiology of rare hereditary diseases.

Hunting for effective treatments, tools offer support in global fight.

BDO Managing Director Patti Seymour discusses the key findings from BDO’s recent life sciences CFO study-and how change and volatility from COVID-19 will reshape fundamental approaches to business sustainability.

eyeforpharma's Blair Gottscho talks about the challenges and opportunities associated with transforming the company’s Barcelona meeting from a live event to a virtual one in light of COVID-19.

Recognizing that diversity and inclusion is no longer simply a “nice to have,” pharma has boosted efforts in this areas. But just how far are new industry initiatives moving the needle on D&I?

Exploring the challenge for pharma in adapting multichannel marketing strategies for the global stage, while trying to refine messages and communicate a brand identity to multiple local audiences.

AstraZeneca’s Habib Bennaceur talks about the key transitions in his career-from local to global-and his current role in positioning AZ’s Farxiga as a drug with the potential to impact the lives of both patients with and without type 2 diabetes.

Philipp Maerz, CEO of Allergopharma talks about how the company has evolved, his recent transition to CEO, and how he plans to expand in the allergy treatment market.

Exploring the advent of data analytics and pharma marketing automation in guiding targeted messaging and brand engagement.